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ABSTRACT: Sepsis is a serious and potentially lethal clinical 
condition characterized by dysregulated immune and systemic 
inflammatory responses (SIRS) to an infection. Although sepsis 
has a high mortality rate (reaching 25% in Europe and North 
America), the clinical interventions available are still limited. 
In the bottom of this exacerbation of the immune response, 
that evolves to immunosuppression and immune paralysis, lies 
epigenetic mechanisms. In sepsis, the balance between activated 
and repressed immune related genes is at lost, and to recover 
that epigenetic based drugs promises to be the future of sepsis 
treatment. Histone deacetylase inhibitors (HDAC’s inhibitors) 
are drugs based in the epigenetic mechanism of acetylation 
and deacetylation of histones, and they have already been 
tested - phases three and four of clinical trials - as treatment for 
other diseases, such as multiple myeloma, and cutaneous t-cell 
lymphoma. Furthermore, experimental studies in sepsis models 
shows that HDAC’s inhibitors are a promising suppressor of 
the exacerbated inflammatory response. Therefore, as the recent 
works shows, epigenetic drugs should be considered a viable 
sepsis therapy in the future. The focus of this review is to present 
the most recent scientific advances in the basic and clinical areas 
of epigenetic as a sepsis treatment, opening opportunities for the 
use of epigenetic in treating this condition.
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RESUMO: Sepse é uma condição clínica grave e potencialmente 
letal caracterizada por desreguladas respostas imunes e 
inflamatórias sistêmicas (SIRS) a uma infecção. Embora a sepse 
tenha uma alta taxa de mortalidade (atingindo 25% na Europa e 
América do Norte), as intervenções clínicas disponíveis ainda são 
limitadas. Por trás dessa exacerbação da resposta imunológica, 
que evolui para a imunossupressão e paralisia imune, residem 
mecanismos epigenéticos. Na sepse, o equilíbrio entre genes 
imunes ativados e reprimidos relacionados é perdido, e reaver 
drogas baseadas na epigenética promete ser o futuro do tratamento 
da sepse. Inibidores da histona desacetilase (inibidores de HDAC) 
são drogas baseadas no mecanismo epigenético de acetilação 
e desacetilação de histonas, e eles já têm sido testados - fases 
três e quatro de ensaios clínicos - como tratamento para outras 
doenças, tais como o mieloma múltiplo, e linfoma cutâneo de 
células T. Além disso, os estudos experimentais em modelos 
de sepse mostram que os inibidores de HDAC são promissores 
supressores da resposta inflamatória exacerbada. Portanto, como 
os trabalhos recentes mostraram, drogas epigenéticas poderiam 
ser consideradas uma viável terapia para a sepse no futuro. O foco 
desta revisão é apresentar os mais recentes avanços científicos 
nas áreas básicas e clínicas de epigenética como um tratamento 
da sepse, abrindo oportunidades para o uso da epigenética no 
tratamento desta condição.
Descritores: Sepse; Epigenética; Inibidor de histona desacetilase.
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INTRODUCTION
Sepsis is a serious and potentially lethal clinical condition characterized by dysregulated 
immune and systemic inflammatory responses (SIRS) 
to an infection. There is an exacerbated and unbalanced 
production of mediators and inflammatory cells, leading 
the patient to a hemodynamic instable state, multiple organ 
dysfunction and death1. 
Although the huge effort by international societies 
(Society of Critical Care Medicine and the European 
Society of Intensive Care Medicine) in developing a 
coordinated bundle care to the treatment of sepsis, the 
mortality of this condition is still very high, reaching 
impressive 25% in Europe and North America. The 
treatment for sepsis is so far been based on antibiotic 
therapy, life support and monitoring. However, it’s low 
efficiency justifies an incessant search for alternative 
therapies able to complement the current one2.
Since in sepsis we found the rising expression 
of specific genes during the inflammatory and immune 
responses, epigenetic – which is a form of DNA expression 
modulation - came out as a potential treatment option 
according to the last ten years studies. Drugs based in 
epigenetic mechanisms, such as acetylation of histones, 
have already been tested as a possible treatment for other 
conditions. Studies based on sepsis physiopathology, 
and experimental studies shows a promising future for 
epigenetic as a treatment for sepsis3. Therefore, the focus 
of this review is to present the most recent scientific 
advances in the basic and clinical areas of epigenetic as a 
sepsis treatment.
Sepsis Physiopathology - Basic Background
Pathogenic microorganisms, when invading 
tissue or blood, forces the host must start an orderly and 
balanced inflammatory response against infection. Any 
microorganism can lead to sepsis in a health person or with 
susceptible clinical conditions (underlying diseases, degree 
of immunosuppression, basal pattern of inflammatory 
response). 
The first step for an inflammatory response is the 
recognition of a molecular pattern present on the cell wall 
or membrane of the microorganism, or a toxin produced 
by it. In bacteria, the most common cause of sepsis, the 
surface molecules lipid A (gram negative) and teichoic 
acid (gram positive) are recognized by Toll-like receptors 
on antigen presenting cells. These cells become activated 
and produce cytokines that have distal and local effects. 
The distal effect refers to attract cells able to phagocyte 
microorganisms (macrophages), and specialized cells to 
coordinate and help fight infection (lymphocytes). The 
local effect of cytokines relates to the constant activation 
of inflammatory cells nearby, amplifying and perpetuating 
the inflammatory state until the situation is controlled. The 
major cytokines produced in this phase are TNF-alpha, 
interleukin-1 and PAF4.
In sepsis, these cytokines can be produced in 
excess, what makes their systemic effects very detrimental 
frequently greater than the toxicity of the bacteria itself. 
Patients with sepsis may present hemodynamic instability 
and multiple organ failure due to the large vasodilator 
power and direct cellular toxicity of these cytokines. The 
presence of a distributive shock only increases perfusion 
damage to organs, especially the kidneys. Other organs 
also affected are lungs, liver, brain, and intestine due to 
presence of inflammatory infiltrate.
The clinical manifestations are nonspecific, which 
demand attention from professional: fever or hypothermia, 
tachycardia, tachypnea, leukocytosis or leukopenia, 
metabolic acidosis, organ failure, decreased saturation, 
confusion, among others4.
Epigenetic - Definitions
Epigenetics can be defined as the “inheritance of 
variation (-genetic) above and beyond (epi-) changes in 
the DNA sequence”5. Cells can change genes availability 
for transcription using the epigenetic machinery, adapting 
phenotypes to different environments, without changing 
the DNA sequence. The changes in the gene availability 
are made through biochemical variations, such as DNA 
methylation, histone modification, and microRNA 
(miRNA).  
These mechanisms can increase or decrease the 
gene products – mRNA transcription, and finally protein 
translation. DNA methylation is the result of the attachment 
of methyl groups to cytosine bases in the DNA sequence, 
made by enzymes called DNA methylases. It decreases 
gene transcription into mRNA, and can be transmitted 
through mitosis or meiosis. Histones are responsible 
for winding and coiling of DNA into nucleosomes and 
then chromatin. r Histones tails can suffer methylation, 
acetylation, ubiquitination or phosphorylation, which 
alter the way DNA will coil around the histone. In 
conclusion, the tightness which chromatin is condensed 
defines the availability of gene sequences. The acetylation 
and deacetylation of histones are the regulators of gene 
expression most used in pharmacology, these reactions 
are controlled by histone acetyltransferases (HATs) and 
histone deacetylases (HDACs). Inhibitors of HDACs, used 
in cancer treatments, has been promising for inflammatory 
diseases, such as sepsis. Finally, miRNA are small, 
noncoding RNAs that regulates different elements in 
transcription and translation. 
Severe sepsis leads to an immune dysfunction. At 
first, there’s an exacerbation of the immune response, which 
evolves to profound immunosuppression and immune 
paralysis. In the bottom of this condition lie epigenetics 
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Inclusion criteria
1. Articles which epigenetic and sepsis were the main focus.
2. Experimental which epigenetic drugs were analysed as a therapy for sepsis.
3. Publication between 2010 and 2016.
4. Clinical trials on phases 3 or 4 which analysed epigenetic drugs as a therapy for other diseases.
5. Articles in English.
Exclusion criteria
1. Articles that describe epigenetic mechanisms in sepsis that aren’t accessible to epigenetic drugs.
2. Review articles.
3. Clinical trials that had no results publicated, except from those that were testing drugs of the experimental studies in sepsis 
selected in this review.
4. Studies that repeated information obtained in previous articles include.
mechanisms described previously. The gene expression 
in mild and severe inflammation is known to be a balance 
between activation of genes and repression of others, which 
leads to homeostasis. Sepsis physiopathology shows us 
that this balance between activated and repressed genes is 
at lost. A better understanding of epigenetics mechanisms 
leads to an important source of possible treatments for 
sepsis, therefore the importance of knowing them, and 
their applicability. 
METHODS
Our main objective in this article was to demonstrate 
the most recent advances by the scientific community 
in reaching a new perspective of treatment in sepsis. To 
this end, we looked for experimental and observational 
studies in animals and in humans that evidenced epigenetic 
mechanisms in the pathophysiology of sepsis and possible 
drugs for therapy. 
We selected articles from 2010 to 2016, using the 
keywords “Epigenetic Sepsis” in the databases PubMed, 
Web of Science and Clinical Trials. PubMed was the 
database where we have found the majority of the studies 
included in our revision (total of 13 articles), followed right 
after by Web of Science (total of 6 articles). No results 
were found in Clinical Trials. Therefore, our analysis of 
epigenetic drugs in humans could not be directly related to 
sepsis treatment, but it had to be adapted to an evaluation 
of their toxicity in others diseases.
The new keywords tested were “histone deacetylase 
inhibitor”. Our choice was based on findings of Eleonora 
Ciarlo in the review “Epigenetics in sepsis: targeting 
histone deacetylases”. The author concludes that inhibiting 
histones deacetylases is the main epigenetic mechanism 
being studied in sepsis so far. The keyword was tested 
in Clinical Trials and Web of Science databases, but not 
PubMed’s because in this last one we already have found 
a lot of articles. 
Only clinical trials on phase 3 or 4 were included 
in this review because it is when, after passing numerous 
toxicity tests, drugs become available for trading. It is our 
chance to demonstrate how reliable epigenetic drugs are 
becoming in medical treatment. 
Other inclusion and exclusion criteria used are 
enumerated above (Image 1).
These criteria were part of our strategy for picking 
up the most suitable articles. Our selection process 
consisted in three steps: reading the studies’ title, abstract 
and entire text. As demonstrated in the next flowcharts, we 
reached a total of 26 articles for this review.
Image 1. Inclusion and exclusion criteria
Flowcharts
Image 2. Method’s flowchart
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RESULTS
From the twenty-six selected works in this 
systematic review, nineteen were observational and seven 
clinical trials. In observational studies, the most common 
sepsis model used was the CLP animal model, totalizing 
five articles, which used in vivo model only. This model 
consist in reproducing a systemic inflammatory process in 
mice by a proliferation stimulus of its own intestinal flora 
bacteria after a section in intestine cecal portion inside 
abdominal cavity. Four in vivo articles used other models, 
such as LPS-induced acute lung injury. Studies that used 
in vitro and in vivo models were the second most common, 
counting six articles. We found three studies which used in 
vitro model only. They reproduce a cellular inflammatory 
status by exposing them to a surface bacteria toxin, the LPS. 
One observational cohort in humans was also 
selected, due its importance in the understanding of 
epigenetic in sepsis physiopathology in humans. Five 
studies were selected for a better understanding of 
epigenetic mechanisms in sepsis physiopathology as well, 
even though they didn’t tested any drug. The drugs most 
tested in the observational studies were Trichostatin A 
(TSA) and Suberoylanilide hydroxamic acid (SAHA), also 
known as Vorinostat. They are both histone deacetylase 
inhibitors, and were found in four studies each. Although 
the majority of substances tested were HDAC inhibitors, 
other epigenetic mechanisms were also found, such as a 
DNA methylation inhibitor (Table 1).
As mentioned earlier, no sepsis study using 
epigenetic drugs was found in humans. Therefore, for 
better understanding the potential toxicity of these drugs, 
we selected twenty clinical trials using HDAC’s inhibitors 
in the treatment of other diseases, mainly cancer (Table 2). 
Despite only four studies had published results, we also 
included clinical trials with no results in this review because 
most of them were testing drugs we found in experimental 
articles in sepsis.
Table 1. Epigenetic drugs mechanisms
Drugs Mechanism Observational Studies
Trichostatin A 
(TSA)
Histone deacetylase 
inhibitor 4
Suberoylanilide 
hydroxamic 
acid (SAHA) or 
Vorinostat
Histone deacetylase 
inhibitor 4
Sodium butyrate 
(SB)
Histone deacetylase 
inhibitor (class I) 3
Tubastatin A Selective histone deacetylase 6 inhibitor 2
Inhibitor 5-Aza 
2-deoxycytidine 
(Aza)
DNA methylation 
inhibitor 1
CG200745 Histone deacetylase inhibitor 1
Va l p r o i c  A c i d 
(Valproate)
Histone deacetylase 
inhibitor
1
LNAME Inhibition of nitric 
oxide activity
1
Compound 9a Histone deacetylase 
inhibitor
1
Curcumin Inhibition of TREM-1 1
Protein C Histone acetylation/
deacetylation regulation
1
Table 2. Epigenetic drugs and their application
Drugs Diseases
Clinical 
Trials  
(N = 20)
Vorinostat
Multiple Myeloma 2
Myelodysplastic syndrome 1*
Cutaneous T-Cell 
Lymphoma 2
Non-Small Cell Lung 
Cancer 1*
Pruritus 1
Mesotelioma 1
Panobinostat
Chronic Myeloid 
Leukemia in Blast Crisis
1
Chronic Myeloid 
Leukemia in Chronic 
Phase 
1
Cutaneous T-Cell 
Lymphoma 2
Myelodysplastic syndrome 1
Multiple Myeloma 2*
Hodgkin’s Lymphoma 1
Valproate Atrofia muscular espinal 1**
Theophylline Bronchiectasis 2**
Sodium butyrate Schizophrenia 1**
*Results available.
** Study included despite not having results available.
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DISCUSSION
The epigenetic research for use in many therapeutic 
areas has proved increasingly promising nowadays. 
However, basic research in the area are still scarce, 
compared to its potential research, especially considering 
major syndromes, such as sepsis. The objective of this 
work is to look in the anthology scientific works that, 
through epigenetic mechanisms, enable the search for drug 
treatments that can treat sepsis, through attenuation of 
inflammatory process or other physiological characteristics 
related to pathophysiological complex. This analysis was 
based on other underlying diseases with inflammatory 
mechanisms, such as cancer and lung diseases, in order 
to correlate the usual mechanisms to sepsis and prevalent 
diseases in the population.
Observational and Experimental Studies
The experimental studies that aims to describe the 
role of epigenetic mechanisms in sepsis physiopathology, 
shows how this mechanism can produce a certain phenotype 
which leads to sepsis. Although the authors don’t test 
any substance, they suggest the possibility of using it 
for epigenetic modification. Comparing monocytes from 
healthy donors to septic patients was showed histones 
modifications in many promoters’ genes regions. As for 
instance, MHC class II locus and its corresponding master 
regulator CIITA, which can be associated to immune 
innate suppression11. Literature reported epigenetic 
modifications in macrophages, in the experimental model 
called “trained immunity”. Mice injected with live C. 
Albicans and primary human monocytes, showed induced 
gene expression through histone modifications, involved 
in glucose metabolism. These changes resulted in aerobic 
glycolysis by AKt-mTOR-HIF-1α pathway, which creates 
a proinflamatory phenotype12.
A murine model of acute lung injury-induced sepsis, 
described the implication of downregulation of Tie2/
angiopoietin (Tie2/Ang) and vascular endothelial growth 
factor, which play important roles in the pathogenesis of 
sepsis. Gene expression downregulations due to histone 
modifications (histone acetyl-lysine modifications, Di- 
and tri-methylation of histone H3 lysine 4, H3K27m3, 
H3K9m2, H3K9m3, and H4K20m3 specifically), showed 
that a decrease in transcription-permissive histone 
modifications in those genes are systemic. The study 
suggests that these modifications could be modulated by 
histones acetylases and deacetylases drugs13. To understand 
the role of H3K4 methyltransferase Ash1l, in the regulation 
of innate immune response, a study used Ash1l-silenced 
mice injected with LPS. They found that Ash1I suppressed 
IL-6 and TNF production in TLR-triggered macrophages, 
thus protecting mice from sepsis14. Epigenetic mechanisms 
has been shown to take part on sepsis physiopathology and 
the studies highlight how these aspects can be targets as 
new therapies in sepsis. 
As mentioned earlier, the drugs most tested in the 
observational studies were Trichostatin A and SAHA, 
histone deacetylase inhibitors (HDACi). By analyzing 
experimental works that seek, through epigenetic 
modifications, enable the production medicines in the 
treatment of sepsis, we found that many mechanisms 
are used for the inhibition of HDAC, which breaks the 
balance between HAT and HDAC. Inhibition of HDAC 
prevents these enzymes act in the removal of acetyl 
groups from DNA strand, thus preventing its chromatin 
condensation (6). Thus, it enables characteristic genotypes 
can fight pathophysiological mechanisms of sepsis, such as 
inflammation. In fact, many substances have been tested 
in several diseases to analyze the epigenetic response, as 
treatment with suberoylanilide hydroxamic acid (SAHA), 
an HDACi, which improved the survival of mice in LPS and 
CLP models, as shown by Ting Zhao et al.7. Its mechanism 
of action involves the factor-kB inhibition by the substance, 
as well as the hypoxia-inducible factor-1a in inflammatory-
mediated pathways, leading to reduced production of 
proinflammatory cytokines. PTX3 molecule (protein 
pentraxin 3) amount increased after accelerated lung injury 
in model mice with high tidal volume ventilation, which 
was counteracted by SAHA reducing their levels in the 
lung and blood8. Rats lethal shock induced by LPS with 
SAHA (50 mg / kg dissolved in dimethyl sulfoxide) before 
and after sepsis induced by LPS, it was found that SAHA 
inhibits inflammatory infiltration in the lungs of animals.
TSA and SAHA were also compared, in a study 
which investigated if septic brain is epigenetically 
modulated by HDACs. The study showed that inhibition 
of HDACs attenuated neuronal apoptosis both in vitro 
(primary hippocampal neuronal) and in vivo (CLP rats). 
Administration of TSA or SAHA improved the spatial 
learning and memory disorders of CLP rats16. Sodium 
butyrate was also an important drug tested in the studies. 
Aiming the to evaluate the effects of a microinjection of 
sodium butyrate (SB, HDACi) into cerebral ventricle on 
aversive memory in rats submitted to the sepsis (CLP 
induction in two groups, one evaluated 24h after the CLP 
induction and other 10 days after). This study showed 
that HDAC activity was increased in the sepsis group in 
hippocampus and cortex in 24 h after CLP induction; and 
in prefrontal cortex and hippocampus 10 days after sepsis. 
Results showed that SB administration reverses only in 
prefrontal cortex and hippocampus at 10 days17. 
Ting Zhao et al.9 showed that tubastatina A 
administration of the murine CLP model reduces thymic 
atrophy during severe sepsis, further reducing apoptosis of 
splenic follicles by inhibition of HDAC6. Moreover, with 
treatment as tubastatina A led to low levels of corticosterone 
in the plasma and an increase of ACTH and since the 
level of cortisol can be forecast sepsis, tubastatina The 
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attenuates the response to stress-induced sepsis, protecting 
also against one of adrenal insufficiency. In addition, Li 
Y et al.10 shows that the inhibition of HDAC6 improves 
survival in murine models of sepsis by PLC, also using 
tubastatina A, which decreased clearance of bacteria in the 
circulation in vivo inhibition RAW264.7 macrophages of 
apoptosis, reduction of pulmonary injury and in the case 
of LPS model for sepsis, decreased levels of inflammatory 
cytokines such as TNF-α and IL-6 in this case LPS models 
of sepsis induction. TSA were tested in an in vitro study 
(THP-1 cells cultivated and submitted to LPS), that analyze 
the effect of tolerance induction with low doses of LPS in 
the cytokine production, and in epigenetic regulation. The 
study showed that low doses of LPS reduced cytokines 
production, and the activity of HAT. This effect was Nitric 
Oxide dependent. The NOS inhibition (with LNAME) 
decreased histone acetylation and blocked the effect of 
tolerance in reducing cytokine release. TSA abolished the 
effect of LPS as well, in the case of IL-1015. 
Table 3. Observational studies evaluated
Study Design Study Goal Epigenetic Mechanism Drug Tested Markers Results
In vitro.
THP-1 cells, 
cultivated and 
submitted to 
LPS.
The effect of tolerance 
induction with low 
doses of LPS in the 
cytokine production, 
and in epigenetic 
regulation. It also 
analyses the role of 
Nitric Oxide in the 
LPS-induced chromatin 
modifications and its 
effects in the cytokine 
production, compared 
with those produced by 
HDAC inhibition.
Histone acetyl 
transferases/histone 
deacetylases (HAT/
HDAC) activity, 
nitrosylation of 
HDAC-2 and 
-3, expression of 
acetylated histones 
H3 and H4. 
Trichostatin 
(TSA) and 
LNAME.
Cytokines 
IL-6 and IL-10 
production, HAT/
HDAC activity, 
nitrosylation of 
HDAC-2 and 
-3, expression of 
acetylated histones 
H3 and H4.
Low doses of LPS reduces 
cytokines production, and the 
activity of HAT. This effect is 
Nitric Oxide dependent.  The 
NOS inhibition (with LNAME) 
decreased histone acetylation 
and blocked the effect of 
tolerance in reducing cytokine 
release. TSA abolished the 
effect of LPS as well, in the 
case of IL-10.
In vivo (LPS-
induced acute 
lung injury in 
mouse).
Efficacy of the DNMT 
inhibitor Aza, the 
HDAC inhibitor TSA, 
and the combination 
of Aza and TSA 
(Aza+TSA) as therapy 
for acute lung injury.
DNA methylation or 
demethylation and 
histone deacetylation 
or acetylation.
DNA methyl 
transferase 
(DNMT) 
inhibitor 5-Aza 
2-deoxycytidine 
(Aza), and the 
HDAC inhibitor 
Trichostatin A 
(TSA).
LPS–TLR4–MAPK 
pathway, 38MAPK 
phosphorylation, 
and TNFα.
Combinatorial Aza+TSA 
therapy is more efficacious than 
therapy with them separately 
in preventing the release of 
LPS-induced chemokines and 
cytokines from macrophages.
Observational 
cohort in 
Humans 
(monocytes 
isolated from 
healthy donors 
and patients 
with sepsis).
Histone modification 
analysis of human 
CD14++ CD16- 
monocytes from 
patients suffering from 
sepsis.
Histone 
modifications 
H3K4me3, 
H3K27me3 and 
H3K9ac.
None.
Genomic locations 
and its distribution 
of H3K4me3, 
H3K27me3 and 
H3K9ac between 
healthy donors and 
patients with sepsis 
with a association 
to the promoter 
regions of many 
genes.
Alterations in the MHC class 
II locus and its corresponding 
master regulator CIITA, 
resulting in reduced activity 
of the later.. Alterations of the 
promoter regions of IL-1β, 
IL1 Receptor 2, was found, 
resulting in down-regulation 
of IL-1β and up-regulation of 
IL1R2, meaning a suppression 
of innate immunity.
In vivo (murine 
model of acute 
lung injury-
induced sepsis)
Implication of 
downregulation of 
Tie2/angiopoietin 
(Tie2/Ang) and 
vascular endothelial 
growth factor receptor-
ligand systems 
(VEGFR/VEGF) genes 
in the pathogenesis 
of sepsis-related 
microvascular leak 
and multiple organ 
dysfunction syndrome.
Histone acetyl-lysine 
modifications, Di- 
and tri-methylation 
of histone H3 lysine 
4, H3K27m3, 
H3K9m2, H3K9m3, 
and H4K20m3.
None.
Tissue albumin 
levels, mRNA 
levels of Tek 
receptor and its 
main cognate 
agonist/ligand, 
Angpt1, Angpt2, 
Vegfα, and Flt1 
(Vegfr1). 
Changes in permissive 
epigenetic histone 
modifications at Angpt1, Tek, 
and Kdr in the lung, kidney, 
and liver. ALI-induced changes 
in repressive epigenetic histone 
modifications at these genetic 
loci were relatively minor. 
Alterations in Angpt1, Tek, 
and Kdr during sepsis may be 
modulated through targeting 
histone acetylases/deacetylases.
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In vivo (murine 
model of CLP).
Evaluated the effects 
of a microinjection of 
sodium butyrate (SB, 
HDACi) into cerebral 
ventricle on aversive 
memory in rats 
submitted to the sepsis. 
Acetylation of 
histones (HDAC) 
activity and 
histone deacetylase 
inhibitors (HDACi).
Sodium butyrate 
(SB, HDACi).
HDAC activity 
in hippocampus, 
cortex, prefrontal 
and striatum.
HDAC activity was increased 
in the sepsis group in 
hippocampus and cortex in 
24 h after CLP induction; 
and in prefrontal cortex and 
hippocampus 10 days after 
sepsis. SB administration 
reverses this only in prefrontal 
cortex and hippocampus at 10 
days.
In vivo (Mice 
injected 
with live C. 
albicans), In 
vitro (primary 
human 
monocytes). 
The study aim is 
to understand the 
mechanism of trained 
immunity in monocytes 
or macrophages, 
through histone 
modifications.
Histone methylation 
and acetylation 
patterns (H3K4me3 
and H3K27ac).
None.
Histone 
modifications and 
RNA sequencing 
analysis, glucose, 
lactate, NAD+ 
and NADH 
concentration, 
cellular O2 
consumption and 
AMPK, mTOR, 
AKT and actin.
Blocking of the mTOR–HIF-
1α pathway, responsible for 
the metabolic shift induced 
by β-glucan, by chemical 
inhibitors inhibited trained 
immunity. The study identified 
glycolysis as a fundamental 
process in trained immunity.
In vivo (CLP in 
BALB/c mice)
The aim was to 
explore how HDAC 
can contribute to 
sepsis-associated 
inflammation and 
apoptosis.
Acetylation of 
histones (HDAC1, 
HDAC2, and 
HDAC3).
CG200745, a 
HDAC inhibitor, 
or valproic acid, 
a inhibitor of 
class I HDACs.
HDAC1, HDAC2, 
and HDAC3.  Bcl-
2. Blood levels of 
TNF, IL-1b, and 
MCP-1.
Sepsis increased histone H3 
and H4 acetylation in lungs. 
CG200745 apoptosis was 
suppressed in lungs and spleens 
of septic mice, but it failed 
to inhibit cytokines and lung 
inflammation. Valproic acid 
also showed antiapoptotic but 
not anti-inflammatory effects in 
septic mice.
In vivo (CLP 
rats), in vitro 
(primary 
hippocampal 
neuronal).
Histone deacetylases 
were implicated in 
neurodegeneration 
and cognitive 
functions. The study 
investigate if septic 
brain is epigenetically 
modulated by HDACs. 
Acetylated histone 3 
(AcH3), acetylated 
histone 4 (AcH4), 
cytoplasmic 
HDAC4.
Trichostatin 
A (TSA) and 
suberoylanilide 
hydroxamic acid 
(SAHA).
Hippocampal 
acetylated 
histone 3 (AcH3) 
and acetylated 
histone 4 (AcH4), 
cytoplasmic 
HDAC4 and 
nuclear HDAC4, 
cytoplasmic and 
nuclear HDAC2. 
Bax and Bcl-XL.
Inhibition of HDACs 
attenuated neuronal apoptosis 
both in vitro and in vivo. 
Administration of HDACs 
inhibitors (TSA or SAHA) also 
improved the spatial learning 
and memory disorders of CLP 
rats.
In vivo (Ash1l-
silenced mice 
injected with 
LPS), in vitro 
(peritoneal 
macrophage).
To understand 
the role of H3K4 
methyltransferases 
and demethylases 
in regulation innate 
inflammatory 
immune responses, 
it was silenced 14 
enzymes involved in 
methylation in mouse 
peritoneal macrophages 
with specific small 
interfering RNAs 
(siRNAs), and then 
measured LPS-induced 
IL-6 production.
Histone 
methyltransferase 
Ash1l (a H3K4 
methyltransferase).
None. IL-6, TNF and 
IFN-β.
Ash1l, a H3K4 
methyltransferase, suppressed 
interleukin-6 (IL-6), and 
tumor necrosis factor (TNF) 
production in Toll-like receptor 
(TLR)-triggered macrophages, 
protecting mice from sepsis.
Study Design Study Goal Epigenetic Mechanism Drug Tested Markers Results
Table 3. Observational studies evaluated         (Cont.)
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In vivo ( G. 
mellonella 
larvae). 
The role of HDACs 
and HATs in epigenetic 
reprogramming during 
metamorphosis, 
wounding and infection 
in the lepidopteran 
model host Galleria 
mellonella.
Acetylation of 
histones by HATs 
and removal of 
acetyl groups by 
HDACs.
Suberoylanilide 
hydroxamic acid 
(SAHA) and 
sodium butyrate.
Expression of 
genes encoding 
components of 
HATs and HDACs, 
and expression of 
MMP, p38 MAP 
kinase, IMPI and 
galiomycin.
Pathogenic bacteria can 
interfere with the regulation of 
HDACs and HATs in insects, 
manipulating host immunity 
and development. The histone 
acetylation/deacetylation in 
insects mediates transcriptional 
reprogramming during 
metamorphosis and in response 
to wounding and infection.
In vivo (CLP 
murine model)
To demonstrate that 
selective
inhibition of HDAC6 
with tubastatin A
displays dramatically 
better survival 
outcomes
compared with 
inhibition of HDAC1, 
2, and 3
in the lethal cecal 
ligation and puncture 
(CLP)
Inhibition of 
HDAC6 Tubastatin A
Cellular apoptosis
measurement
Blunting of the stress
responses, attenuated thymic 
and bone
marrow atrophy and decreased 
apoptosis in
splenic follicles.
In vitro 
(RAW264.7 
cells) and 
in vivo 
(Polymicrobial 
sepsis was 
induced by CLP 
in mice)
To investigate the 
protective
mechanisms of a newly 
synthetized HDAC 
inhibitor, Compound
9a, in sepsis, 
particularly with regard 
to MAPK signalling
associated with 
inflammation.
Inhibition of 
HDAC1, after 
trying with HDAC1, 
HDAC2 and 
HDAC3
Compound 9a
ALT, AST, 
creatinine, BUN 
and LDH.
It inhibited MAPK-mediated 
inflammatory
responses and attenuated the 
organ damage.
In vivo (mouse 
primary 
splenocytes)and 
in vitro (RAW 
264.7 murine 
macrophages)
To determine if 
selective inhibition 
of HDAC6 has a 
substantial advantage 
for sepsis treatment.
Inhibition of 
HDAC6 Tubastatin A
TNF-α and IL-6 
and inhibits 
cell apoptosis 
of RAW264.7 
macrophages
It improves survival and 
decreases cytokine levels in 
peritoneal fluid and circulation.
In vivo (mice in 
LPS model)
To use
high-throughput 
methods to investigate 
the multidimensional
impact of SAHA 
treatment on
gene expression 
profiles at an early 
stage of
LPS-induced shock
Attenuation of 
inflammatory 
mediators
including (TNFR1 
and 2, TRAF6, TLR-
2, PTX3,
MyD88, CCL3)
SAHA TLR-4, TNF-a, 
IL-1b
It attenuates
inflammation and decreases 
neutrophil infiltration
in the lungs
In vivo (mice 
in LPS model) 
and in vitro 
(primary bone 
marrow derived 
macrophages)
To investigate the 
effects of curcumin 
on the
expression of TREM-1 
in vitro in primary bone 
marrow derived
macrophages and in 
vivo in a septic lung 
injury model
It attenuates 
methylation and 
acetylation of 
histone
3 and 4 in the 
TREM-1 promoter
Curcumin IL-6, IL-10 and TNF-a Reduction septic lung injury
Table 3. Observational studies evaluated                                                                                                                                     (Cont.)
Study Design Study Goal Epigenetic Mechanism Drug Tested Markers Results
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In vitro (Human 
monocyte 
derived 
macrophages)
To investigate
novel targets for the 
anti-inflammatory 
action of APC in 
human macrophages
Effect on HDACs 
activity Protein C
Comparison 
between two 
samples
(LPS/INFc and 
LPS/INFc/APC)
APC down-regulates the 
mRNA level of IL-1b, IL-8, 
MCP-1 and MIP-1b and the 
protein expression of MCP-1, 
and MIP-1b in
macrophages
In vivo (CLP 
model in mice)
To demonstrate that 
HDAC inhibitors
effectively attenuate 
LPS-induced 
inflammation in vitro 
and in vivo
It decreased the
MPO activities in 
lung homogenates, 
moreover it 
downregulated
the expression 
of ICAM-1 and 
E-selectin
Trichostatin 
A (TSA) and 
sodium butyrate 
(SB)
IL-6
HDACs control injury from 
inflammation
In vivo (CLP 
sepsis model)
To characterize 
the coagulation 
abnormalities
in a lethal CLP model 
using TEG, and to
assess the effects of 
SAHA treatment on 
these
disturbances
It restores fibrin 
cross-linkage time 
in a
lethal, moreover it 
improves platelet 
function
SAHA TNF-a and IL-6 It prevented coagulopathy
In vitro (blood 
samples
collected from 
sepsis subjects 
with septic 
shock and 
multiorgan
failure and 
healthy controls)
To demonstrate that 
TLR4 stimulation
and human sepsis 
activate pathways that 
couple NAD and its
sensor SIRT1 
with epigenetic 
reprogramming
SIRT1 Deacetylates 
RelA/p65 at Lysine 
310 at Promoters to
Limit Gene 
Transcription of 
Proinflammatory 
Cytokine Genes. 
Moreover, it 
activates RelB 
transcription
None TNF-a It represses transcription of
TNF-a and IL-1
Table 3. Observational studies evaluated                                                                                                                      (Cont.)
Study Design Study Goal Epigenetic Mechanism Drug Tested Markers Results
Clinical Trials Studies
In clinical trials the most studied drugs nowadays 
are Panobinostat and SAHA, especially for the treatment 
of hematological malignancies such as types of lymphoma 
and leukemia (see Table). However, the drugs theophylline, 
sodium butyrate and valproate are being tested in the 
treatment of other conditions in which gene expression 
regulation is also a pathophysiological factor. These 
diseases are spinal muscular atrophy, bronchiectasis and 
schizophrenia.
In bronchiectasis study, experimental findings that 
justify the use of HDAC resemble to sepsis’ because it 
evaluates theophylline effect over inflammatory process. 
In this clinical trial, theophylline is a possible target-
therapy for bronchiectasis due to its anti-inflammatory 
results of previous studies for the treatment of COPD 
and asthma. The hypothesis is that theophylline has no 
inhibitory action, but directly increases the activity of 
histone deacetylases by downregulating the expression 
and production of interleukins such as IL-8, enhancing 
corticosteroids’ effect27.
On the other hand, other clinical trial evidenced that 
the use of valproate as an inhibitor of histone deacetylase, 
led to increased SMN 1(survival motor neuron 1) 
expression, which is deleted gene in 95% of patients with 
Spinal Muscular Atrophy28.
Therefore, it is important to consider that the final 
effect of epigenetic drugs may not be predictable. Not 
necessarily, these drugs will provide less gene expression in 
all genetic code. Actually, there is a risk of over expression, 
which side effects are yet unknown, justifying further 
investigation for each situation.
Studies with oncologic patients, the only with 
results, analyzed the use of SAHA and Panabinostat drugs. 
In general, almost all participants in control groups and 
groups exposed to new combination therapy had some type 
of adverse event. In relation to the most common serious 
adverse events (see Table 4), the control group showed a 
lower percentage of patients with the outcome, suggesting 
that the tested HDAC’s could lead to further complications. 
However, most studies did not show statistical analysis of 
the data, not allowing affirm that difference between the 
groups is significant. Moreover, it is important to consider 
that these studies were conducted in oncologic patients 
with a higher degree of clinical fragility.
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Table 4. Adverse Events
Drug
Disease Adverse Events Serious Adverse Events Most common 
Serious Adverse 
Events
Refe- 
rence
Experimental Control Experimental Control
Panobinostat/
LBH589
Multiple 
Myeloma
53/55 
(96.36%)
- 39/55 
(70%) -
Pneumonia
Thrombocytopenia 
Pyrexia
23
Panobinostat/
LBH589
Multiple 
Myeloma
379/381 
(99.48%)
366/377 
(97.08%)
228/381 
(59.84%)
157/377 
(41.64%)
Diarrhoea
Pneumonia 24
Vorinostat/ 
SAHA
Non-Small Cell 
Lung Cancer
114/124 
(91.94%)
117/124 
(94.35%)
63/124 
(50.81%)
45/124 
(36.29%)
Febrile neutropenia
Neutropenia 25
Vorinostat/ 
SAHA
Myelodysplastic 
Syndrome
91/91 
(100.00%)
89/91 
(97.80%) 47/91 (51.65%)
8/91 
(8.79%)
Anemia
Pneumonia
Thrombocytopenia
26
Table 5. Progression-free survival
Drug Disease
Progression-free Survival
Unit Reference
Experimental Control
Panobinostat/LBH589 Multiple Myeloma 164.0 (107.0 to 204.0) - Days 23
Panobinostat/LBH589 Multiple Myeloma 11.99 (10.32 to 12.94)
8.80 
(7.56 to 9.23) Months 24
Vorinostat/ SAHA Non-Small Cell Lung Cancer 4.3 (0.03 to 13.4)
5.5 
(0.03 to 13.8) Months 25
Vorinostat/ SAHA Myelodysplastic Syndrome 455 * 311 (182 to 640) Days 26
*The upper limit of the confidence interval cannot be estimated.
To compare these drugs efficiency in studies, we 
chose the parameter “progression-free survival” (Table 5). 
Analyzing the table, in almost all clinical trials the use of 
HDAC in experimental group led to increase disease-free 
time. The progression of the disease in each study was 
assessed differently, in most cases considering the result 
of imaging and laboratory. Just as mentioned before, the 
studies showed no statistical analysis, being impossible to 
assert significant difference. According to these clinical 
trials, HDAC’s inhibitors have a toxic action in neoplasia 
because they are able to promote accumulation of cytotoxic 
misfolded protein aggregates and dysregulate neoplasic cell 
function, leading to its death24.
CONCLUSION
After all those works analyses, it is clear that septic 
patients have epigenetic alterations. When exposed to an 
infection the expression changes in immune related genes, 
creates a phenotype that results in an exacerbated pro-
inflammatory cytokines release and inflammatory cells 
production, characterizing sepsis. 
The new findings in epigenetic alterations in sepsis 
physiopathology, shed a light in a new possible treatment 
based on epigenetic drugs. Although studies in vitro or in 
vivo pointed the use of HDAC’s inhibitors as a promising 
suppressor of the exacerbated inflammatory response in 
sepsis models, we still have to be careful with their use in 
humans for mainly two reasons: 
Firstly, severe adverse effects, like cytopenias, 
observed in cancer patients from HDAC’s Clinical Trials 
should be considered in the treatment of sepsis treatment 
as well. The balance between immune and inflammatory 
response must our final goal for having success in sepsis 
treatment. Secondly, no clinical parameters for sepsis were 
totally evaluated in the experimental studies selected, which 
we strongly recommend for next researches.
As no studies in humans using epigenetic drugs for 
the treatment of sepsis were found, we are able to affirm 
that the translational between basic and clinical areas is still 
not finished. The use of epigenetic drugs in other diseases, 
specially in studies on phases three or four, shows that 
toxicity in humans have been overcome. Therefore, if the 
development of new studies in this area pursues, epigenetic 
drugs should be considered as viable sepsis therapy.
101
Rev Med (São Paulo). 2016 abr.-jun.;95(2):91-102.
REFERENCES
1. Vachharajani V, Liu T, McCall C. Epigenetic coordination 
of acute systemic inflammation: potential therapeutic 
targets. Expert Rev Clin Immunol. 2014;10(9):1141-50. doi: 
10.1586/1744666X.2014.943192.
2. Rhodes A, Phillips G, Beale R, Cecconi M, Chiche J, De 
Backer D, et al. The surviving sepsis campaign bundles 
and outcome: results from the International Multicentre 
Prevalence Study on Sepsis (the IMPreSS study). Intensive 
Care Med. 2015;41(9):1620-8. doi: 10.1007/s00134-015-
3906-y. 
3. Ciarlo E, Savva A, Roger T. Epigenetics in sepsis: targeting 
histone deacetylases. Int J Antimicrob Agents. 2013;42:S8-
S12. doi: 10.1016/j.ijantimicag.2013.04.004.
4. Pereira Junior GA, Marson F, Abeid M, Ostini FM, Souza 
SH, Basile-Filho A. Pathogenetic mechanisms of sepsis and 
their therapeutics implications. Medicina, Ribeirão Preto. 
1998;31:349-62.
5. Bonasio R, Tu S, Reinberg D. Molecular signals of epigenetic 
states. Science. 2010;330(6004):612-616. doi: 10.1126/
science.1191078.
6. Menditi KBC, Hye CK. The role of histones proteins 
in hematological neoplasias. Rev Bras Cancerol. 
2007;53(4):453-60.
7. Zhao T, Li Y, Liu B, Wu E, Sillesen M, Velmahos G, et 
al. Histone deacetylase inhibitor treatment attenuates 
coagulation imbalance in a lethal murine model of 
sepsis. Surgery. 2014;156(2):214-20. doi: 10.1016/j.
surg.2014.04.022.
8. Li Y, Liu B, Gu X, Kochanek A, Fukudome E, Velmahos G, 
et al. Creating a “pro-survival” phenotype through epigenetic 
modulation. J Surg Res. 2012;172(2):199. doi: 10.1016/j.
surg.2012.06.036.
9. Zhao T, Li Y, Bronson R, Liu B, Velmahos G, Alam H. 
Selective histone deacetylase-6 inhibition attenuates stress 
responses and prevents immune organ atrophy in a lethal 
septic model. Surgery. 2014;156(2):235-42. doi: 10.1016/j.
surg.2014.03.033.
10. Li Y, Zhao T, Liu B, Halaweish I, Mazitschek R, Duan X, et 
al. Inhibition of histone deacetylase 6 improves long-term 
survival in a lethal septic model. J Trauma Acute Care Surg. 
2015;78(2):378-85. doi: 10.1097/TA.0000000000000510.
11. Weiterer S, Uhle F, Lichtenstern C, Siegler B, Bhuju S, 
Jarek M et al. Sepsis induces specific changes in histone 
modification patterns in human monocytes. PLOS ONE. 
2015;10(3):e0121748. doi: 10.1371/journal.pone.0121748.
12. Cheng S, Quintin J, Cramer R, Shepardson K, Saeed S, 
Kumar V, et al. mTOR- and HIF-1 -mediated aerobic 
glycolysis as metabolic basis for trained immunity. Science. 
2014;345(6204):1250684. doi: 10.1126/science.1250684
13. Bomsztyk K, Mar D, An D, Sharifian R, Mikula M, Gharib 
S, et al. Experimental acute lung injury induces multi-organ 
epigenetic modifications in key angiogenic genes implicated 
in sepsis-associated endothelial dysfunction. Crit Care. 
2015;19(1). doi: 10.1186/s13054-015-0943-4.
14. Xia M, Liu J, Wu X, Liu S, Li G, Han C, et al. Histone 
Methyltransferase Ash1l Suppresses Interleukin-6 
Production and Inflammatory Autoimmune Diseases by 
Inducing the Ubiquitin-Editing Enzyme A20. Immunity. 
2013;39(3):470-81. doi: 10.1016/j.immuni.2013.08.016.
15. Rios E, de Lima T, Moretti A, Soriano F. The role of 
nitric oxide in the epigenetic regulation of THP-1 induced 
by lipopolysaccharide. Life Sci. 2016;147:110-16. doi: 
10.1016/j.lfs.2016.01.041.
16. Fang J, Lian Y, Xie K, Cai S, Wen P. Epigenetic modulation 
of neuronal apoptosis and cognitive functions in sepsis-
associated encephalopathy. Neurol Sci. 2013;35(2):283-8. 
doi: 10.1007/s10072-013-1508-4.
17. Steckert A, Comim C, Igna D, Dominguini D, Mendonça 
B, Ornell F, et al. Effects of sodium butyrate on aversive 
memory in rats submitted to sepsis. Neurosci Lett. 
2015;595:134-8. doi: 10.1016/j.neulet.2015.04.019.
18. Kim S, Baek K, Park H, Jung Y, Lee S. Compound 9a, a 
novel synthetic histone deacetylase inhibitor, protects against 
septic injury in mice by suppressing MAPK signalling. Brit 
J Pharmacol. 2016;173(6):1045-57. doi: 10.1111/bph.13414.
19. Yuan Z, Syed M, Panchal D, Rogers D, Joo M, Sadikot 
R. Curcumin mediated epigenetic modulation inhibits 
TREM-1 expression in response to lipopolysaccharide. Int 
J Biochem Cell Biol. 2012;44(11):2032-43. doi: 10.1016/j.
biocel.2012.08.001.
20. Pereira C, Bachli E, Schaer D, Schoedon G. Transcriptome 
analysis revealed unique genes as targets for the anti-
inflammatory action of activated protein C in human 
macrophages. PLoS ONE. 2010;5(10):e15352. doi: 10.1371/
journal.pone.0015352.
21. Zhang L, Jin S, Wang C, Jiang R, Wan J. histone deacetylase 
inhibitors attenuate acute lung injury during cecal ligation 
and puncture-induced polymicrobial sepsis. World J Surg. 
2010;34(7):1676-83. doi: 10.1007/s00268-010-0493-5.
22. Liu T, Yoza B, El Gazzar M, Vachharajani V, McCall 
C. NAD+-dependent SIRT1 deacetylase participates in 
epigenetic reprogramming during endotoxin tolerance. 
J Biol Chem. 2011;286(11):9856-64. doi: 10.1074/jbc.
M110.196790.
23. Richardson P, Schlossman R, Alsina M, Weber D, Coutre 
S, Gasparetto C, et al. PANORAMA 2: panobinostat in 
combination with bortezomib and dexamethasone in patients 
with relapsed and bortezomib-refractory myeloma. Blood. 
2013;122(14):2331-7. doi: 10.1182/blood-2013-01-481325.
24. Novartis (Novartis Pharmaceuticals). Panobinostat or 
placebo with bortzomib and dexamethasone in patients with 
relapsed multiple myeloma (PANORAMA-1). ClinicalTrials.
gov [Internet]. 2015 [cited 2016 Feb 17]. Available from: 
https://clinicaltrials.gov/ct2/show/NCT01023308.
102
Bonizzio CR, et al. The viability of using epigenetic drugs as a treatment of patients in sepsis.
25. Merck Sharp & Dohme Corp. A clinical trial of vorinostat 
(MK0683, SAHA) in combination with FDA approved 
cancer drugs in patients with advanced Non-small Cell 
Lung Cancer (NSCLC)(0683-056). ClinicalTrials.gov 
[Internet]. 2015 [cited 2016 Feb 17]. Available from: https://
clinicaltrials.gov/ct2/show/NCT00473889.
26. National Cancer Institute (NCI). Azacitidine with or without 
lenalidomide or vorinostat in treating patients with higher-
risk myelodysplastic syndromes or chronic myelomonocytic 
leukemia. ClinicalTrials.gov [Internet]. 2016 [cited 2016 
Feb 17]. Available from: https://clinicaltrials.gov/ct2/show/
NCT01522976.
27. The First Affiliated Hospital of Guangzhou Medical 
University. The role of theophylline plus low-dose 
formoterol-budesonide in treatment of bronchiectasis. 
ClinicalTrials.gov [Internet]. 2015 [cited 2016 Feb 
17]. Available from: https://clinicaltrials.gov/ct2/show/
NCT01769898.
28. All India Institute of Medical Sciences, New Delhi. 
Valproate and levocarnitine in children with spinal muscular 
atrophy. ClinicalTrials.gov [Internet]. 2015 [cited 2016 Feb 
17]. Available from: https://clinicaltrials.gov/ct2/show/
NCT01671384.
29. Smith RC, Nathan Kline Institute for Psychiatric Research. 
Sodium butyrate for improving cognitive function in 
schizophrenia. ClinicalTrials.gov [Internet]. 2016 [cited 
2016 Feb 17]. Available from: https://clinicaltrials.gov/ct2/
show/NCT02654405.
